Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Inclusion Criteria

• •Histologically confirmed classical Hodgkin's lymphoma
• •* No bone marrow biopsies or fine needle aspirates as the sole means of diagnosis
• •* Core biopsies allowed if they contain adequate tissue for primary diagnosis
• •The following subtypes are allowed:
• •* Nodular sclerosis
• •* Lymphocyte rich
• •* Mixed cellularity
• •* Lymphocyte depletion
• •* Classical Hodgkin's lymphoma, not otherwise specified
• •No nodular lymphocyte-predominant Hodgkin's lymphoma
• •Relapsed or refractory disease after at least 1 prior standard systemic cytotoxic chemotherapy regimen
• •Measurable disease by physical exam or imaging studies
• •* Any tumor mass \> 1 cm is allowed
• •* No non-measurable disease only, including the following:
• •* Bone lesions
• •* Ascites
• •* Pleural or pericardial effusion
• •* Lymphangitis cutis/pulmonis
• •* Bone marrow
• •No curative option available with high-dose therapy and stem cell transplantation
• •Performance status - 0-2
• •Absolute neutrophil count ≥ 750/mm\^3
• •Platelet count ≥ 75,000/mm\^3
• •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• •AST ≤ 2.5 times ULN
• •Creatinine ≤ 2.5 mg/dL
• •No sensory or motor peripheral neuropathy ≥ grade 2
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for up to 3 months after study participation
• •See Disease Characteristics
• •Prior stem cell transplantation allowed
• •See Disease Characteristics
• •No concurrent chemotherapy
• •No concurrent dexamethasone or other steroidal antiemetics
• •* Concurrent steroids for adrenal failure allowed
• •Concurrent hormonal therapy for non-disease related conditions (e.g., insulin for diabetes) allowed
• •Prior radiotherapy to a symptomatic lesion or one that may produce disability (e.g., unstable femur) is allowed provided other measurable disease is present
• •No concurrent palliative radiotherapy
• •Recovered from all prior treatment
• •No prior bortezomib or other proteosome inhibitors